Biosight’s Less Toxic Chemo BST-236 Wins FDA Fast Track Status for AML
News
Biosight‘s BST-236 (aspacytarabine), a less toxic form of chemotherapy for acute myeloid leukemia (AML), has received fast track designation from the U.S. Food and Drug Administration (FDA) for patients ages 75 ... Read more